Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β

FEBS Journal

Volumn 281, Issue 1, 2014, Pages 3-13

  Kawakami, Fumitaka ^a   Shimada, Naoki ^a   Ohta, Etsuro ^a   Kagiya, Go ^a   Kawashima, Rei ^a   Maekawa, Tatsunori ^a   Maruyama, Hiroko ^a   Ichikawa, Takafumi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

glycogen synthase kinase 3 (GSK 3 ); leucine rich repeat kinase 2 (LRRK2); Parkinson's disease (PD); phosphorylation; Tau

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LEUCINE RICH REPEAT KINASE 2; PROTEIN SERINE KINASE; PROTEIN SERINE KINASE 396; TAU PROTEIN; UNCLASSIFIED DRUG;

CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE FIBER GROWTH; NERVE FIBER TRANSPORT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 84891832231     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12579     Document Type: Review

References (19)

1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al,. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.
2. Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, Lincoln SJ, Cobb SA, Rajput ML, &, Farrer MJ, (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506-1508.
3. Cookson MR, Hardy J, &, Lewis PA, (2008) Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 1, 217-231.
4. Houlden H, &, Singleton AB, (2012) The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 124, 325-338.
5. Ujiie S, Hatano T, Kubo S, Imai S, Sato S, Uchihara T, Yagishita S, Hasegawa K, Kowa H, Sakai F, et al,. (2012) LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat Disord 18, 819-823.
6. Ruffmann C, Giaccone G, Canesi M, Bramerio M, Goldwurm S, Gambacorta M, Rossi G, Tagliavini F, &, Pezzoli G, (2012) Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism. Neuropathol Appl Neurobiol 38, 382-386.
7. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, et al,. (2009) Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12, 826-828.
8. Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, et al,. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40, 503-517.
9. Gillardon F, (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J Neurochem 110, 1514-1522.
10. Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, &, Obata F, (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS ONE 7, e30834.
11. Lin CH, Tsai PI, Wu RM, &, Chien CT, (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK-3β. J Neurosci 30, 13138-13149.
12. Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K, Maruyama H, &, Ichikawa T, (2011) Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β. FEBS J 278, 4895-4904.
13. Kawakami F, Yamaguchi A, Suzuki K, Yamamoto T, &, Ohtsuki K, (2008) Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3β and the GSK-3β-mediated phosphorylation of myelin basic protein in vitro. J Biochem 143, 359-367.
14. Li T, Yang D, Sushchky S, Liu Z, &, Smith WW, (2011) Models for LRRK2-linked Parkinsonism. Parkinsons Dis 2011, Article ID: 942412.
15. Ballatore C, Lee VM, &, Trojanowski JQ, (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
16. Kitazawa M, Trinh DN, &, LaFerla FM, (2008) Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 64, 15-24.
17. Sarlus H, Höglund CO, Karshikoff B, Wang X, Lekander M, Schultzberg M, &, Oprica M, (2012) Allergy influences the inflammatory status of the brain and enhances tau-phosphorylation. J Cell Mol Med 16, 2401-2412.
18. Ohta E, Katayama Y, Kawakami F, Yamamoto M, Tajima K, Maekawa T, Iida N, Hattori S, &, Obata F, (2009) I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem Biophys Res Commun 390, 710-715.
19. Fountaine TM, &, Wade-Martins R, (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 85, 351-363.